Synonyms EE1A1, EEF1A, eEF1A-1 + [13] |
Introduction Translation elongation factor that catalyzes the GTP-dependent binding of aminoacyl-tRNA (aa-tRNA) to the A-site of ribosomes during the elongation phase of protein synthesis (PubMed:26651998, PubMed:26593721, PubMed:36264623, PubMed:36123449, PubMed:36638793). Base pairing between the mRNA codon and the aa-tRNA anticodon promotes GTP hydrolysis, releasing the aa-tRNA from EEF1A1 and allowing its accommodation into the ribosome (PubMed:26651998, PubMed:26593721, PubMed:36264623, PubMed:36123449, PubMed:36638793). The growing protein chain is subsequently transferred from the P-site peptidyl tRNA to the A-site aa-tRNA, extending it by one amino acid through ribosome-catalyzed peptide bond formation (PubMed:26651998, PubMed:26593721, PubMed:36264623, PubMed:36123449). Also plays a role in the positive regulation of IFNG transcription in T-helper 1 cells as part of an IFNG promoter-binding complex with TXK and PARP1 (PubMed:17177976).
(Microbial infection) Required for the translation of viral proteins and viral replication during human coronavirus SARS-CoV-2 infection. |
Target |
Mechanism EEF1A1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. AU |
First Approval Date10 Dec 2018 |
Target |
Mechanism EEF1A1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Target |
Mechanism EEF1A1 inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Start Date30 May 2023 |
Sponsor / Collaborator |
Start Date19 Apr 2023 |
Sponsor / Collaborator |
Start Date18 Jan 2022 |
Sponsor / Collaborator Pharma Mar SA [+1] |